Codex DNA (NASDAQ:DNAY) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Codex DNA (NASDAQ:DNAYGet Rating) from a sell rating to a hold rating in a research note released on Tuesday morning, reports.

According to Zacks, “Codex DNA Inc. is a creator of the BioXp(TM) system, a fully automated benchtop instrument which enables numerous synthetic biology workflows. Codex DNA Inc. is based in SAN DIEGO. “

Several other brokerages have also weighed in on DNAY. Cowen initiated coverage on shares of Codex DNA in a report on Wednesday, March 2nd. They set a buy rating for the company. KeyCorp reduced their price target on shares of Codex DNA from $30.00 to $8.00 and set an overweight rating on the stock in a research report on Monday, March 28th.

Shares of DNAY stock opened at $4.15 on Tuesday. The firm has a market cap of $122.00 million and a P/E ratio of -1.82. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.48 and a quick ratio of 5.33. Codex DNA has a 1-year low of $3.43 and a 1-year high of $25.70. The firm has a fifty day moving average of $4.67 and a two-hundred day moving average of $7.00.

Codex DNA (NASDAQ:DNAYGet Rating) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.05. Codex DNA had a negative net margin of 311.52% and a negative return on equity of 46.56%. On average, sell-side analysts expect that Codex DNA will post -2.03 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. Citigroup Inc. lifted its position in shares of Codex DNA by 221.0% in the 4th quarter. Citigroup Inc. now owns 2,838 shares of the company’s stock worth $31,000 after buying an additional 1,954 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Codex DNA by 87.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,554 shares of the company’s stock valued at $60,000 after purchasing an additional 2,584 shares during the last quarter. Wells Fargo & Company MN lifted its position in Codex DNA by 1,245.5% in the 4th quarter. Wells Fargo & Company MN now owns 3,606 shares of the company’s stock valued at $39,000 after purchasing an additional 3,338 shares during the last quarter. California State Teachers Retirement System bought a new stake in Codex DNA in the 3rd quarter valued at about $47,000. Finally, American International Group Inc. bought a new stake in Codex DNA in the 3rd quarter valued at about $47,000. Institutional investors own 87.58% of the company’s stock.

About Codex DNA (Get Rating)

Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

See Also

Get a free copy of the Zacks research report on Codex DNA (DNAY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Codex DNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codex DNA and related companies with's FREE daily email newsletter.